ADME of Antibody–Maytansinoid Conjugates

@article{Erickson2012ADMEOA,
  title={ADME of Antibody–Maytansinoid Conjugates},
  author={Hans K. Erickson and J. G. Lambert},
  journal={The AAPS Journal},
  year={2012},
  volume={14},
  pages={799-805}
}
The concept of treating cancer with antibody-drug conjugates (ADCs) has gained momentum with the favorable activity and safety of trastuzumab emtansine (T-DM1), SAR3419, and lorvotuzumab mertansine (IMGN901). All three ADCs utilize maytansinoid cell-killing agents which target tubulin and suppress microtubule dynamics. Each ADC utilizes a different optimized chemical linker to attach the maytansinoid to the antibody. Characterizing the absorption, distribution, metabolism, and excretion (ADME… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Target-cell processing of the anti-CD19 antibody maytansinoid conjugate SAR3419 in preclinical models

  • HK Erickson, P C, MF Mayo, WC Widdison, C Audette
  • AACR Abstract
  • 2009
Highly Influential
10 Excerpts

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

  • S Girish, GuptaM, +11 authors A. Joshi
  • Cancer Chemother Pharmacol
  • 2012
3 Excerpts

Similar Papers

Loading similar papers…